1. National Cancer Institute Surveillance, Epidemiology, and End Results Program . Cancer stat facts: prostate cancer, https://seer.cancer.gov/statfacts/html/prost.html (2020, accessed 1 November 2020).
Google Scholar2. Freedland, SJ, Humphreys, EB, Mangold, LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433–439.
Google Scholar | Crossref | Medline | ISI3. Kupelian, PA, Mahadevan, A, Reddy, CA, et al. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer. Urology 2006; 68: 593–598.
Google Scholar | Crossref | Medline4. Tabakin, AL, Sadimin, ET, Tereshchenko, I, et al. Correlation of prostate cancer CHD1 status with response to androgen deprivation therapy: a pilot study. J Genitourin Disord 2018; 2: 1006.
Google Scholar | Medline5. Shorning, BY, Dass, MS, Smalley, MJ, et al. The PI3K-AKT-mtor pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci 2020; 21: 4507.
Google Scholar | Crossref6. Butler, DE, Marlein, C, Walker, HF, et al. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget 2017; 8: 56698–56713.
Google Scholar | Crossref | Medline7. Kumar-Sinha, C, Tomlins, SA, Chinnaiyan, AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497–511.
Google Scholar | Crossref | Medline | ISI8. Hollenhorst, PC, Ferris, MW, Hull, MA, et al. Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev 2011; 25: 2147–2157.
Google Scholar | Crossref | Medline9. Robinson, D, Van Allen, EM, Wu, YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215–1228.
Google Scholar | Crossref | Medline | ISI10. Cai, C, Wang, H, He, HH, et al. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest 2013; 123: 1109–1122.
Google Scholar | Crossref | Medline11. Kunderfranco, P, Mello-Grand, M, Cangemi, R, et al. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One 2010; 5: e10547.
Google Scholar | Crossref | Medline12. Sun, C, Dobi, A, Mohamed, A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348–5353.
Google Scholar | Crossref | Medline | ISI13. Geybels, MS, Alumkal, JJ, Luedeke, M, et al. Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors. Clin Epigenetics 2015; 7: 128.
Google Scholar | Crossref | Medline14. Barbieri, CE, Baca, SC, Lawrence, MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685–689.
Google Scholar | Crossref | Medline | ISI15. Liu, W, Lindberg, J, Sui, G, et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 2012; 31: 3939–3948.
Google Scholar | Crossref | Medline16. Skene, PJ, Hernandez, AE, Groudine, M, et al. The nucleosomal barrier to promoter escape by RNA polymerase II is overcome by the chromatin remodeler Chd1. Elife 2014; 3: e02042.
Google Scholar | Crossref | Medline17. Ocampo, J, Chereji, RV, Eriksson, PR, et al. The ISW1 and CHD1 ATP-dependent chromatin remodelers compete to set nucleosome spacing in vivo. Nucleic Acids Res 2016; 44: 4625–4635.
Google Scholar | Crossref | Medline18. Kimura, K, Tsuzuki, T, Kato, M, et al. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 2014; 74: 680–687.
Google Scholar | Crossref | Medline19. Siggens, L, Cordeddu, L, Ronnerblad, M, et al. Transcription-coupled recruitment of human CHD1 and CHD2 influences chromatin accessibility and histone H3 and H3.3 occupancy at active chromatin regions. Epigenetics Chromatin 2015; 8: 4.
Google Scholar | Crossref | Medline20. Gaspar-Maia, A, Alajem, A, Polesso, F, et al. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 2009; 460: 863–868.
Google Scholar | Crossref | Medline | ISI21. Koh, FM, Lizama, CO, Wong, P, et al. Emergence of hematopoietic stem and progenitor cells involves a Chd1-dependent increase in total nascent transcription. Proc Natl Acad Sci U S A 2015; 112: E1734–E1743.
Google Scholar | Crossref | Medline22. Kari, V, Mansour, WY, Raul, SK, et al. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep 2016; 17: 1609–1623.
Google Scholar | Crossref | Medline23. Hu, Y, Smyth, GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009; 347: 70–78.
Google Scholar | Crossref | Medline | ISI24. Pinto, MP, Jacobsen, BM, Horwitz, KB. An immunohistochemical method to study breast cancer cell subpopulations and their growth regulation by hormones in three-dimensional cultures. Front Endocrinol (Lausanne) 2011; 2: 15.
Google Scholar | Crossref | Medline25. Lindskog, M, Laurell, A, Kjellman, A, et al. A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma. J Clin Oncol 2020; 38(Suppl. 5): 11.
Google Scholar | Crossref | Medline26. Grasso, CS, Wu, YM, Robinson, DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012; 487: 239–243.
Google Scholar | Crossref | Medline | ISI27. Shtivelman, E, Beer, TM, Evans, CP. Molecular pathways and targets in prostate cancer. Oncotarget 2014; 5: 7217–7259.
Google Scholar | Crossref | Medline28. Belden, WJ, Lewis, ZA, Selker, EU, et al. CHD1 remodels chromatin and influences transient DNA methylation at the clock gene frequency. PLoS Genet 2011; 7: e1002166.
Google Scholar | Crossref | Medline29. Baca, SC, Prandi, D, Lawrence, MS, et al. Punctuated evolution of prostate cancer genomes. Cell 2013; 153: 666–677.
Google Scholar | Crossref | Medline | ISI30. Huang, S, Gulzar, ZG, Salari, K, et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 2012; 31: 4164–4170.
Google Scholar | Crossref | Medline31. Bello, D, Webber, MM, Kleinman, HK, et al. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997; 18: 1215–1223.
Google Scholar | Crossref | Medline | ISI32. Desgrosellier, JS, Cheresh, DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9–22.
Google Scholar | Crossref | Medline | ISI33. Ramirez, NE, Zhang, Z, Madamanchi, A, et al. The α2β1 integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest 2011; 121: 226–237.
Google Scholar | Crossref | Medline34. Zutter, MM, Santoro, SA, Staatz, WD, et al. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc Natl Acad Sci U S A 1995; 92: 7411–7415.
Google Scholar | Crossref | Medline | ISI35. Bonkhoff, H, Stein, U, Remberger, K. Differential expression of alpha 6 and alpha 2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum Pathol 1993; 24: 243–248.
Google Scholar | Crossref | Medline36. Guadamillas, MC, Cerezo, A, Del Pozo, MA. Overcoming anoikis– pathways to anchorage-independent growth in cancer. J Cell Sci 2011; 124: 3189–3197.
Google Scholar | Crossref | Medline | ISI37. Perlino, E, Lovecchio, M, Vacca, RA, et al. Regulation of mRNA and protein levels of beta1 integrin variants in human prostate carcinoma. Am J Pathol 2000; 157: 1727–1734.
Google Scholar | Crossref | Medline | ISI38. Gassmann, P, Haier, J. The tumor cell-host organ interface in the early onset of metastatic organ colonisation. Clin Exp Metastasis 2008; 25: 171–181.
Google Scholar | Crossref | Medline39. Harma, V, Virtanen, J, Makela, R, et al. A Comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010; 5: e10431.
Google Scholar | Crossref | Medline | ISI40. Gorlov, IP, Byun, J, Gorlova, OY, et al. Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. BMC Med Genomics 2009; 2: 48.
Google Scholar | Crossref | Medline41. Huynh, MH, Zhu, SJ, Kollara, A, et al. Knockdown of SPARC leads to decreased cell-cell adhesion and lens cataracts during post-gastrula development in Xenopus laevis. Dev Genes Evol 2011; 220: 315–327.
Google Scholar | Crossref | Medline42. Said, N, Frierson, HF, Chernauskas, D, et al. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 2009; 28: 3487–3498.
Google Scholar | Crossref | Medline43. Chung, IC, Chen, LC, Chung, AK, et al. Matrix metalloproteinase 12 is induced by heterogeneous nuclear ribonucleoprotein K and promotes migration and invasion in nasopharyngeal carcinoma. BMC Cancer 2014; 14: 348.
Google Scholar | Crossref | Medline44. Wen, X, Wang, H, Chai, P, et al. An artificial CTCF peptide triggers efficient therapeutic efficacy in ocular melanoma. Mol Ther Oncolytics 2020; 18: 317–325.
Google Scholar | Crossref | Medline45. Xie, J, Yang, P, Lin, HP, et al. Integrin α4 up-regulation activates the hedgehog pathway to promote arsenic and benzo[α]pyrene co-exposure-induced cancer stem cell-like property and tumorigenesis. Cancer Lett 2020; 493: 143–155.
Google Scholar | Crossref | Medline46. Wang, M, Nagle, RB, Knudsen, BS, et al. A basal cell defect promotes budding of prostatic intraepithelial neoplasia. J Cell Sci 2016; 130: 104–110.
Google Scholar | Medline